Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223435 | 0.89 | FOLH1 (0.41) | FOLH1SMN1; SMN2HPGDHTTITGB3 | |
| SCHEMBL22223441 | 0.89 | FOLH1 (0.41) | FOLH1SMN1; SMN2HPGDHTTITGB3 | |
| SCHEMBL24589101 | 0.88 | FOLH1 (0.39) | FOLH1SMN1; SMN2HPGDHTTITGB3 | |
| SCHEMBL24588972 | 0.82 | PTGS1 (0.42) | FOLH1SMN1; SMN2HPGDHTTITGB3 | |
| SCHEMBL24589067 | 0.81 | FOLH1 (0.36) | FOLH1SMN1; SMN2HPGDHTTALDH1A1 | |
| SCHEMBL22223438 | 0.80 | FOLH1 (0.40) | FOLH1SMN1; SMN2HPGDHTTITGB3 | |
| SCHEMBL24589068 | 0.78 | FOLH1 (0.39) | FOLH1SMN1; SMN2HPGDHTTITGB3 | |
| SCHEMBL24589088 | 0.78 | FOLH1 (0.39) | FOLH1SMN1; SMN2HPGDHTTITGB3 | |
| SCHEMBL22223335 | 0.78 | FOLH1 (0.43) | FOLH1SMN1; SMN2HPGDHTTITGB3 | |
| SCHEMBL24589089 | 0.77 | FOLH1 (0.33) | FOLH1SMN1; SMN2HPGDHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | FOLH1 1272/4885SMN1; SMN2 3727/4885HPGD 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.